Blood Res 2014; 49(3): 205-207
Second case of postpartum acquired hemophilia A in a Korean female
Kun Soo Lee1*, Ye Jee Shim2, Kyoung Mi Jang1, and Shin Young Hyun3

1Department of Pediatrics, Kyungpook National University Hospital and Kyungpook National University School of Medicine, Daegu, Korea.

2Hanyoung Children's Hospital, Daegu, Korea.

3Department of Medicine, Yonsei University Wonju College of Medicine, Wonju, Korea.

Correspondence to: Correspondence to: Kun Soo Lee. Department of Pediatrics, Kyungpook National University Hospital and School of Medicine, 130 Dongdukro, Jung-gu, Daegu 700-721, Korea.
Received: August 6, 2014; Revised: August 22, 2014; Accepted: September 19, 2014; Published online: September 25, 2014.
© The Korean Journal of Hematology. All rights reserved.

cc This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

TO THE EDITOR: Acquired hemophilia A (AHA) is a very rare condition with an incidence of about 1.5 per million of the general population per year [1]. It develops in middle age due to autoantibody production directly against the factor VIII (FVIII) and occurs in both sexes equally. The underlying conditions associated with AHA are other autoimmune diseases, malignancy, drugs and pregnancy. However, about half of AHA has no specific cause, thus they are called idiopathic. Postpartum AHA is a special category with distinct clinical manifestation contributing to 7-21% of patients with AHA [2, 3, 4]. In Korea, the first case of postpartum AHA in a 40 years old female has been reported by Lee et al. [5]. To the best of our knowledge, the present case report is the second one in Korea.

A previously healthy 18 years old female had several minor bruises on hands and feet at 5 months after delivery. There was no specific complication immediately after delivery. She previously didn't take any drugs which could result in AHA and her family history was nonspecific. The hemorrhagic symptoms were aggravated during the process of time and she visited a private medical doctor at 8 months after delivery. At the medical clinic, she was only supplemented with iron to treat her iron deficiency anemia. Because of a persistent migrating painful swelling on her knees and ankle joints, multiple bruises and menorrhagia, she was transferred to our institute at 9 months after delivery.

Her initial laboratory test results were as follows: PT 10.2 sec (normal range, 10-14 sec), INR 0.95 (normal range, 0.85-1.50), aPTT 84.3 sec (normal range, 20-40 sec), FVIII activity 1.4% (moderately decreased), and anti-FVIII antibody 28 Bedestha units (BU). Thus, she was confirmed as postpartum AHA. To manage her persisting hemorrhagic symptoms, activated prothrombin complex concentrate, FEIBA (Baxter, Westlake Village, CA, USA) was infused to her based on the dose for joint hemorrhage (50-100 units/kg every 12 hours until pain/disabilities are improved, maximum 200 units/kg/day) and her bleeding symptoms resolved. We closely followed up her at the outpatient clinic with on-demand FEIBA injection. After 2 months, the last follow up PT/aPTT were 11.2/95.1 sec, FVIII activity 1.5% and anti-FVIII antibody 40 BU. We consider giving corticosteroid to her additionally.

According to European Acquired Haemophilia (EACH2) registry, 42 cases of postpartum AHA developed from 2003 to 2008 in 13 European countries [4]. In other words, the medical personnel in hematology or obstetrics can experience one postpartum AHA patient every year or biyearly in one country. Because time to diagnosis of postpartum AHA was 21-120 days after delivery, pregnant women should be observed closely approximately 1-3 months after delivery [4].

Usually, AHA is often misunderstood as another bleeding disorder like disseminated intravascular coagulation because a hemorrhage into the skin (purpura) or soft tissue is the most common presenting sign of AHA, while a hemarthrosis, the hole mark of a congenital hemophilia, occurs rarely [1, 2]. According to EACH2, hemarthrosis was also a rare hemorrhagic symptom of postpartum AHA contributing about 5%. Subcutaneous (45%) or mucosal bleeding (43%) was most common. On the other hand, in case of our report, the patient was mistaken as to have rheumatic disease because the migrating painful swelling of her joints due to hemarthrosis was the main symptom.

The treatment of acute bleeding in case of postpartum AHA is not different from the general form. Two bypassing agents, FEIBA and the recombinant activated factor VII, NovoSeven (Novo Nordisk, Princeton, NJ, USA) are the main therapeutic agents to control acute hemorrhagic symptoms. The overall complete response rate of hemorrhages using FEIBA was 86% with the infusion of 75 units/kg every 8 to 12 hours [6]. And the efficacy rate using NovoSeven was 95% as first line therapy for AHA [7]. NovoSeven has some advantages that it's blood born viral transmission is shut out and the risk of thromboembolism is lower than that of FEIBA [8, 9].

The combination of bypassing agents for stopping the hemorrhage and immunosuppressive therapy is usually used together to eradicate the autoantibodies of FVIII in the general form of AHA. Prednisolone (prednisone), cyclophosphamide, azathioprine, 6-mercaptopurine, rituximab (anti-CD 20 monoclonal antibody), mycophenolate or cyclosporin have been used for treatment [1, 3, 10, 11, 12].

However, the immunosuppression may be individually reserved considering the advantages and disadvantages in case of postpartum AHA because of its more favorable prognosis compared to the general form. In retrospective reviews of postpartum AHAs, 86-100% of patients showed complete remission and survival rate was 97-100% [4, 12]. Further, there was no statistical difference of the time to complete remission between the postpartum AHA patients had immunosuppressive therapy and the rest of cohort [4]. On the other hand, the course of a general AHA is quite different. The relapse rate was about 20% after the cessation of immunosuppression and the survival rate was about 60% [1].

In some international survey, the recurrence rate of postpartum AHA was 0% [13, 14]. However, there is a controversy over the recurrence rate of anti-FVIII antibody in case of subsequent pregnancy. Large-scaled study about the recurrence rate is not available yet. Thus the patients who experienced postpartum AHA should be observed carefully after subsequent pregnancies.

In the previous Korean case of postpartum AHA reported by Lee et al. [5], the patient was treated with a bypassing agent plus corticosteroid. In the present case, we are using on-demand FEIBA infusion for control of acute bleeding and postponed the immunosuppression considering a spontaneous remission. In our present case, the hemorrhagic symptoms of the patient were now solved using FEIBA. We expect that case presentations will help to increase the awareness on this rare condition among the medical personnel in the hematologic and obstetric field.

  1. Collins, PW, Hirsch, S, Baglin, TP, et al. Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation. Blood, 2007;109;1870-1877.
  2. Yee, TT, Taher, A, Pasi, KJ, Lee, CA. A survey of patients with acquired haemophilia in a haemophilia centre over a 28-year period. Clin Lab Haematol, 2000;22;275-278.
  3. Huth-Kuhne, A, Baudo, F, Collins, P, et al. International recommendations on the diagnosis and treatment of patients with acquired hemophilia A. Haematologica, 2009;94;566-575.
  4. Tengborn, L, Baudo, F, Huth-Kuhne, A, et al. Pregnancy-associated acquired haemophilia A: results from the European Acquired Haemophilia (EACH2) registry. BJOG, 2012;119;1529-1537.
  5. Lee, JH, Kim, DH, Yoo, K, Choi, Y, Kim, SH, Kim, HJ. The first case of postpartum acquired hemophilia A in Korea. J Korean Med Sci, 2011;26;1247-1249.
  6. Sallah, S. Treatment of acquired haemophilia with factor eight inhibitor bypassing activity. Haemophilia, 2004;10;169-173.
  7. Sumner, MJ, Geldziler, BD, Pedersen, M, Seremetis, S. Treatment of acquired haemophilia with recombinant activated FVII: a critical appraisal. Haemophilia, 2007;13;451-461.
  8. Aledort, LM. Factor VIII inhibitor bypassing activity (FEIBA) - addressing safety issues. Haemophilia, 2008;14;39-43.
  9. Abshire, T, Kenet, G. Safety update on the use of recombinant factor VIIa and the treatment of congenital and acquired deficiency of factor VIII or IX with inhibitors. Haemophilia, 2008;14;898-902.
  10. Lee, YS, Ng, HJ. Mycophenolate in the remission induction of a patient with acquired haemophilia A. Haemophilia, 2010;16;180-182.
  11. Petrovic, M, Derom, E, Baele, G. Cyclosporine treatment of acquired hemophilia due to factor VIII antibodies. Haematologica, 2000;85;895-896.
  12. Hauser, I, Schneider, B, Lechner, K. Post-partum factor VIII inhibitors. A review of the literature with special reference to the value of steroid and immunosuppressive treatment. Thromb Haemost, 1995;73;1-5.
  13. Coller, BS, Hultin, MB, Hoyer, LW, et al. Normal pregnancy in a patient with a prior postpartum factor VIII inhibitor: with observations on pathogenesis and prognosis. Blood, 1981;58;619-624.
  14. Baudo, F, de Cataldo, F. Acquired factor VIII inhibitors in pregnancy: data from the Italian Haemophilia Register relevant to clinical practice. BJOG, 2003;110;311-314.


This Article

Current Issue


Indexed/Covered by

Today : 133  /
Total : 226,875